Inotiv, Inc. to Report Fiscal 2025 First Quarter Financial Results and Host Conference Call on Wednesday, February 5, 2025
Inotiv (NASDAQ: NOTV), a contract research organization focused on nonclinical and analytical drug discovery services, has scheduled its fiscal 2025 first quarter financial results announcement for Wednesday, February 5, 2025, after market close. The results will cover the period ended December 31, 2024.
The company will host a conference call at 4:30 p.m. Eastern Time on the same day to discuss the results. Participants can join via phone using the following numbers: 1-800-579-2543 (Domestic) or 1-785-424-1789 (International), with Conference ID: INOTIV. A live webcast will be available through the company's Investors section website, with a replay accessible afterward.
Inotiv (NASDAQ: NOTV), un'organizzazione di ricerca a contratto focalizzata sui servizi di scoperta di farmaci non clinici e analitici, ha programmato l'annuncio dei risultati finanziari per il primo trimestre fiscale 2025 per mercoledì 5 febbraio 2025, dopo la chiusura del mercato. I risultati copriranno il periodo chiuso il 31 dicembre 2024.
La società ospiterà una conferenza telefonica alle 16:30, ora orientale, lo stesso giorno per discutere i risultati. I partecipanti possono unirsi per telefono utilizzando i seguenti numeri: 1-800-579-2543 (Nazionali) o 1-785-424-1789 (Internazionali), con ID Conferenza: INOTIV. Una webconferenza dal vivo sarà disponibile attraverso la sezione Investitori del sito web della società, con una registrazione accessibile successivamente.
Inotiv (NASDAQ: NOTV), una organización de investigación por contrato centrada en servicios de descubrimiento de fármacos no clínicos y analíticos, ha programado el anuncio de sus resultados financieros del primer trimestre fiscal 2025 para el miércoles 5 de febrero de 2025, después del cierre del mercado. Los resultados cubrirán el período que finalizó el 31 de diciembre de 2024.
La empresa realizará una llamada de conferencia a las 4:30 p.m. hora del Este el mismo día para discutir los resultados. Los participantes pueden unirse por teléfono utilizando los siguientes números: 1-800-579-2543 (Nacional) o 1-785-424-1789 (Internacional), con ID de Conferencia: INOTIV. Una retransmisión en vivo estará disponible a través de la sección de Inversores del sitio web de la empresa, con una grabación accesible posteriormente.
Inotiv (NASDAQ: NOTV), 비임상 및 분석 약물 발견 서비스에 중점을 둔 계약 연구 조직이 2025 회계연도 첫 분기 재무 결과 발표를 2025년 2월 5일 수요일, 시장 폐장 후에 예정했습니다. 결과는 2024년 12월 31일에 종료된 기간을 다룹니다.
회사는 같은 날 동부 표준시 오후 4:30에 결과를 논의하기 위한 컨퍼런스 콜을 개최합니다. 참가자는 다음 번호로 전화를 통해 참여할 수 있습니다: 1-800-579-2543 (국내) 또는 1-785-424-1789 (국제), 컨퍼런스 ID: INOTIV. 회사의 투자자 섹션 웹사이트를 통해 생방송 웹캐스트가 제공되며, 이후에는 다시보기도 가능합니다.
Inotiv (NASDAQ: NOTV), une organisation de recherche sous contrat axée sur les services de découverte de médicaments non cliniques et analytiques, a programmé l'annonce de ses résultats financiers du premier trimestre de l'exercice 2025 pour le mercredi 5 février 2025, après la fermeture du marché. Les résultats couvriront la période se terminant le 31 décembre 2024.
L'entreprise organisera une conférence téléphonique à 16h30, heure de l'Est, le même jour pour discuter des résultats. Les participants peuvent se joindre par téléphone en utilisant les numéros suivants : 1-800-579-2543 (domestique) ou 1-785-424-1789 (international), avec l'identifiant de conférence : INOTIV. Un webinaire en direct sera disponible sur la section investisseurs du site web de l'entreprise, avec un accès à une rediffusion par la suite.
Inotiv (NASDAQ: NOTV), eine Vertragsforschungsorganisation, die sich auf nichtklinische und analytische Arzneimittelentdeckungsdienste konzentriert, hat die Bekanntgabe ihrer Finanzergebnisse für das erste Quartal des Geschäftsjahres 2025 für Mittwoch, den 5. Februar 2025, nach Börsenschluss angesetzt. Die Ergebnisse werden den Zeitraum bis zum 31. Dezember 2024 abdecken.
Das Unternehmen wird am selben Tag um 16:30 Uhr Eastern Time eine Telefonkonferenz abhalten, um die Ergebnisse zu besprechen. Teilnehmer können sich telefonisch über die folgenden Nummern einwählen: 1-800-579-2543 (inländisch) oder 1-785-424-1789 (international), mit der Konferenz-ID: INOTIV. Eine Live-Übertragung wird über den Investorenbereich der Unternehmenswebsite verfügbar sein, mit einer späteren Wiederholung.
- None.
- None.
WEST LAFAYETTE, Ind., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that it will issue its financial results for the fiscal 2025 first quarter ended December 31, 2024, on Wednesday, February 5, 2025, after the close of the stock market. The Company will host a conference call that same day at 4:30 p.m. Eastern Time to discuss the results.
Interested parties may participate in the call by dialing:
- 1-800-579-2543 (Domestic)
- 1-785-424-1789 (International)
- INOTIV (Conference ID)
The live conference call webcast will be accessible in the Investors section of the Company’s web site and directly via the following link:
https://viavid.webcasts.com/starthere.jsp?ei=1703666&tp_key=aaee0f56f1
For those who cannot listen to the live broadcast, an online replay will be available in the Investors section of Inotiv’s web site at: https://ir.inotiv.com/events-and-presentations/default.aspx.
About Inotiv
Inotiv, Inc. is a leading contract research organization dedicated to providing nonclinical and analytical drug discovery and development services and research models and related products and services. The Company’s products and services focus on bringing new drugs and medical devices through the discovery and preclinical phases of development, all while increasing efficiency, improving data, and reducing the cost of taking new drugs to market. Inotiv is committed to supporting discovery and development objectives as well as helping researchers realize the full potential of their critical R&D projects, all while working together to build a healthier and safer world. Further information about Inotiv can be found here: https://www.inotiv.com/.
This release may contain forward-looking statements that are subject to risks and uncertainties including, but not limited to, risks and uncertainties related to the impact of recent events related to non-human primate matters on the Company’s business, operations, results, financial condition, cash flows, and assets, the Company’s ability to comply with covenants under its credit agreement, compliance with the Resolution and Plea Agreements with the DOJ and the expected impacts on the Company related to the compliance plan, compliance monitor, and the expected financial commitments, changes in the market and demand for the Company’s products and services, the development, marketing and sales of products and services, changes in technology, industry and regulatory standards, the timing of acquisitions and the successful closing, integration and business and financial impact thereof, governmental regulations, inspections and investigations, claims and litigation against or involving the Company, its business and/or its industry, the impact of site closures and consolidations, expansion and related efforts, and various other market and operating risks, including those detailed in the Company's filings with the U.S. Securities and Exchange Commission.
| Company Contact | Investor Relations |
| Inotiv, Inc. | LifeSci Advisors |
| Beth A. Taylor, Chief Financial Officer | Steve Halper |
| (765) 497-8381 | (646) 876-6455 |
| beth.taylor@inotiv.com | shalper@lifesciadvisors.com |
FAQ
When will Inotiv (NOTV) release its Q1 2025 earnings?
How can investors join Inotiv's (NOTV) Q1 2025 earnings call?
What period does Inotiv's (NOTV) Q1 2025 earnings report cover?
Where can I find the replay of Inotiv's (NOTV) Q1 2025 earnings call?
